OS Therapies (NYSE: OSTX) is a cancer immunotherapy company engaged in the development of new treatments for osteosarcoma and other solid tumors.
OS Therapies is actively advancing its osteosarcoma immunotherapy: CEO Paul Romness
Categories
pharmaceuticals
Earnings Summary: Quest Diagnostics (DGX) reaffirms FY25 guidance
Quest Diagnostics Incorporated (NYSE: DGX), a provider of diagnostic information services, has reaffirmed its outlook for fiscal 2025 and provided cautious first-quarter
Illumina (ILMN) expects adjusted EPS of approximately $4.50 for FY25
Biotechnology company Illumina, Inc. (NASDAQ: ILMN) has issued fresh earnings guidance for fiscal 2025, to reflect tariff-related challenges to export. The company
Earnings Summary: Highlights of Baxter International’s Q4 2024 report
Baxter International Inc. (NYSE: BAX) on Thursday announced financial results for the fourth quarter of 2024. The medical device maker's sales increased
MDT Earnings: Medtronic reports higher Q3 2025 revenue and adj. profit
Medical device maker Medtronic plc (NYSE: MDT) on Tuesday reported an increase in revenues and adjusted profit for the third quarter of
Earnings Summary: Moderna slips to loss in Q4; revenue down 66%
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) has reported a net loss for the fourth quarter of 2024, compared to a profit last
Earnings: CVS Health reports a sharp fall in Q4 profit; revenue up 4%
Healthcare conglomerate CVS Health Corporation (NYSE: CVS) reported mixed results for the fourth quarter of 2024, with revenues growing modestly and earnings
Highlights of Bristol-Myers Squibb’s Q4 2024 earnings report
Biotechnology company Bristol Myers Squibb (NYSE: BMY) reported lower profit for the fourth quarter of 2024, despite an increase in revenue. Net
LLY Earnings: Eli Lilly Q4 2024 profit more than doubles; revenue up 45%
Eli Lilly and Company (NYSE: LLY) Thursday reported a sharp increase in its fourth-quarter revenues. The pharmaceutical company's adjusted earnings more than
MRK Earnings: Merck Q4 2024 adj. profit jumps on strong sales growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the fourth quarter of 2024, aided
PFE Earnings: Key quarterly highlights from Pfizer’s Q4 2024 financial results
Pfizer Inc. (NYSE: PFE) reported its fourth quarter 2024 earnings results today. Revenues increased 22% year-over-year to $17.8 billion. GAAP net income
AbbVie Q4 2024 adjusted earnings decline despite 6% revenue growth
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced fourth-quarter 2024 financial results, reporting a double-digit dip in adjusted earnings and an increase in
Important takeaways from Abbott Laboratories’ Q4 2024 earnings report
Abbott Laboratories (NYSE: ABT) reported mixed results for the final months of fiscal 2024 and issued guidance for the first quarter and
Highlights of Abbott Laboratories (ABT) Q4 2024 results
Abbott Laboratories (NYSE: ABT) on Wednesday announced financial results for the fourth quarter of 2024, reporting an increase in sales and adjusted
JNJ Earnings: All you need to know about Johnson & Johnson’s Q4 2024 earnings results
Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2024 earnings results today. Reported sales increased 5.3% year-over-year to $22.5 billion. Operational
Johnson & Johnson (JNJ) likely to report mixed results for Q4 2024
Johnson & Johnson (NYSE: JNJ) is set to publish its December-quarter report on January 22, amid expectations for mixed results. The company,
AngioDynamics (ANGO) reports net loss for Q2 2025; sales drop 8%
AngioDynamics Inc. (NASDAQ: ANGO) reported a net loss for the second quarter of 2025 as the medical device company’s revenues decreased 8%.
NeOnc Technologies plans to go public through direct listing
NeOnc Technologies Holdings Inc., a privately held clinical-stage biotechnology company that develops therapies to improve the treatment of brain tumors and central
“Gelteq has been continuously evolving to expand applications and audiences”
Gelteq Limited (NASDAQ: GELS) is a healthcare company specializing in the development and manufacturing of edible gel products, with a focus on
Pfizer (PFE) reaffirms FY24 forecast; provides FY25 guidance
Pharmaceutical company Pfizer Inc. (NYSE: PFE) Tuesday reaffirmed its financial outlook for fiscal 2024 and provided guidance for fiscal 2025. The company
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that